
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics Inc. has demonstrated promising clinical efficacy through its gene therapy product candidates, particularly in ophthalmology, evidenced by significant visual acuity gains and a notable reduction in injection burdens for patients. The company possesses a strong financial position with an extended cash runway of $505 million projected to sustain operations into 2028, which is strategically advantageous for advancing pivotal trial readouts. Furthermore, 4D's commitment to targeted therapies and alignment with environmental, social, and governance (ESG) principles enhances its growth trajectory, positioning the company favorably for sustainable success in the gene therapy market.
Bears say
4D Molecular Therapeutics faces significant risks that contribute to a negative outlook on its stock, including the potential failure to replicate positive early-stage data in later trials, which could lead to downward price revisions. The company reported a substantial net loss of $160.9 million for the full year 2024, reflecting its non-revenue generating status and the unpredictability of future earnings, underscoring concerns about its financial viability. Additionally, challenges related to manufacturing capacity and the complexity of producing its gene therapy products could hinder the development and commercialization of its product candidates, further exacerbating its financial risks.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares